Branched-chain amino acid therapy for spinocerebellar degeneration: A pilot clinical crossover trial

Internal Medicine

Volumn 38, Issue 5, 1999, Pages 401-406

  Mori, Nozomi ^a   Adachi, Yoshiki ^a   Takeshima, Takao ^a   Kashiwaya, Yoshihiro ^a   Okada, Akitsugu ^a   Nakashima, Kenji ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

Ataxia; Posturography method; Spinocerebellar degeneration (SCD) score; Thyrotropin releasing hormone tartrate (TRHT)

Indexed keywords

AMINOLEBAN; BRANCHED CHAIN AMINO ACID; PROTIRELIN; UNCLASSIFIED DRUG;

ADULT; AGED; AKINESIA; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HUMAN; MALE; RIGIDITY; SPINOCEREBELLAR DEGENERATION;

EID: 0033060145     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.38.401     Document Type: Article

References (13)

1. Sobue I, Takayanagi T, Nakanishi T, et al. Controlled trial of thyrotropin releasing hormone tartrate in ataxia of spinocerebellar degenerations. J Neurol Sci 61: 235-248, 1983.
2. Wessel K, Langenberger K, Nitschke MF, Kömpf D. Double-blind cross-over study with physostigmine in patients with degenerative cerebellar diseases. Arch Neurol 54: 397-400, 1997.
3. Waragai M, Ogawara K, Takaya Y, Hayashi M. Efficacy of TRH-T for spinocerebellar degeneration - the relation between clinical features and effect of TRH therapy. Rinsho Shinkeigaku (Clin Neurol) 37: 587-594, 1997 (Abstract in English).
4. Hattori T, Asahina M, Shinoto H, Arai K, Hirayama K. Effect of a single dose of intravenous thyrotropin releasing hormone on postural instability in patients with cerebellar degeneration: a double-blind cross over study. Annual report of the Research Committee of Ataxic Diseases, the Ministry Health and Welfare of Japan, 1996: 61-64 (Abstract in English).
5. Yudkoff M. Brain metabolism of branched-chain amino acids. Glia 21: 92-98, 1997.
6. Mori N, Adachi Y, Takeshima T, et al. A trial of amino acid therapy against spinocerebellar degeneration. Annual report of the Research Committee of Ataxic Diseases, the Ministry Health and Welfare of Japan, 1998: 48-50 (in Japanese).
7. Hirayama K, Takayanagi T, Nakamura R, et al. Spinocerebellar degenerations in Japan: a nationwide epidemiological and clinical study. Acta Neurol Scand Suppl 153: 1-22, 1994.
8. Plaitakis A, Smith J, Mandeli J, Yahr MD. Pilot trial of branched-chain aminoacids in amyotrophic lateral sclerosis. Lancet 1: 1015-1018, 1988.
9. Testa D, Caraceni T, Fetoni V. Branched-chain amino acids in the treatment of amyotrophic lateral sclerosis. J Neurol 236: 445-447, 1989.
10. The Italian ALS Study Group. Branched-chain amino acids and amyotrophic lateral sclerosis: A treatment failure? Neurology 43: 2466-2470, 1993.
11. Tandan R, Bromberg MB, Forshew D, et al. A controlled trial of amino acid therapy in amyotrophic lateral sclerosis: I. Clinical, functional, and maximum isometric torque data. Neurology 47: 1220-1226, 1996.
12. Trouillas P, Takayanagi T, Hallett M, et al, and The Ataxia Neuropharmacology Committee of the World Federation of Neurology. International Cooperative Ataxia Rating Scale for pharmacological assessment of the cerebellar syndrome. J Neurol Sci 145: 205-211, 1997.
13. Pincus JH, Barry KM. Plasma levels of amino acids correlate with motor fluctuations in parkinsonism. Arch Neurol 44: 1006-1009, 1987.